HOME >> BIOLOGY >> NEWS
Rockefeller University researchers discover immune-cell mechanism that boosts therapeutic antibody potency

Researchers at The Rockefeller University, in collaboration with Genentech, Inc., have made a surprising discovery about the mechanism by which two currently used clinical antibodies fight tumors. The finding, reported in the April issue of Nature Medicine, has immediate implications for increasing the potency of an entire class of cancer drugs now on the market and for developing more effective drugs in the future.

"This should have a significant impact on immunotherapy for cancer," says senior author Jeffrey V. Ravetch, M.D., Ph.D., Theresa and Eugene M. Lang Professor and head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology at Rockefeller. "There are more than 20 other antibodies now being developed that are in various stages of clinical trials, and this finding shows a way to make them much more effective."

The scientists discovered that two anti-tumor antibodies, Herceptin and Rituxan, operate by harnessing the immune system and directing it to kill tumor cells. The antibodies connect to the immune system by engaging receptor pairs on the surface of certain immune cells. One of these receptors acts as an "on" switch to initiate an immune response, while the other acts as an "off" switch to hold the immune system in check and prevent it from attacking the body.

As effective as Herceptin and Rituxan are, the researchers found that removing or disabling the "off" switch could make an antibody many times more potent than before. Ravetch says the technology to do so is within reach.

"It's startling to learn that these antibodies do not work the way everyone has assumed," Ravetch says. "Now that we recognize this in vivo mechanism, we should be able to manipulate it to great effectiveness."

Antibodies are natures own defense against foreign intruders. Antibody molecules comprise two main segments: a variable region, which is highly specific in order to recognize any foreign shapeor pathogenit may encounter; and the Fc do
'"/>

Contact: Jim Stallard
stallaj@rockvax.rockefeller.edu
212-327-8977
Rockefeller University
27-Mar-2000


Page: 1 2 3 4

Related biology news :

1. Rockefeller University scientists take on controversial vibration theory of smell
2. By the year 2050, human population could add 2.6 billion people, reports Rockefeller scientist
3. White House awards National Medal of Science to Rockefeller Universitys James Darnell
4. Lasker Award honors Rockefeller University biochemist for pioneering studies of gene activation
5. Rockefeller scientists identify natural proteins that push stem cells to produce hair, not skin
6. Rockefeller, Weill Cornell researchers find link between estrogen, brain structure changes
7. Rockefeller researchers provide the first functional evidence for mammalian pheromone receptors
8. Another transmembrane protein structure solved by Rockefeller scientists
9. Rockefeller researchers identify defense system in plants
10. Rockefeller University Centennial Symposium to explore biology of drug abuse and addiction
11. Rockefeller and Aaron Diamond researchers say resistance to HIV drugs may be higher than previously thought

Post Your Comments:
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... W. R. Grace & Co. (NYSE: ... Germany has received good manufacturing practice (GMP) certification ... Pharmaceutical Excipient Council (IPEC) Foundation. , ... FP brand of pharmaceutical grade excipient silica gels ... Bay, Maryland (USA) and Sorocaba, Brazil locations. The ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... May 20, 2015 Research and Markets ... of the "2015 Global Survey on Flow ... The primary goal of this research ... instruments and reagents. Key information the survey seeks ... of flow cytometers, predominantly used applications for flow ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: